Introduction
============

Despite a global decline in incidence, there are about 2.2 million new cases of gastric cancer per year, resulting in 834 thousand deaths, making gastric cancer the second leading cause of cancer related mortality worldwide [@B1]. Since 1989, when Dubois et al. first reported their experience with laparoscopic cholecystectomy [@B2], abdominal surgery has increasingly moved toward a minimally invasive approach due to the many advantages regarding improvements in patient quality of life during the postoperative period. Laparoscopic approaches for gastric cancer in particular have been slowly accepted in the west, largely due to the lower incidence of gastric cancer in these countries. Currently, laparoscopic distal, subtotal, and total gastrecomy for early and advanced gastric cancer are emerging in the west with progressive acceptance among various groups [@B3]-[@B5]. Because several epidemiologic differences exist between east and west, the delayed acceptance of gastrectomy may be partly related to skepticism regarding the oncological efficacy of laparoscopic surgery. However, few studies have focused on the outcomes of the use of laparoscopic techniques for gastric cancer between Eastern and Western countries.

We present data from the International study group on Minimally Invasive surgery for GASTRIc Cancer (IMIGASTRIC) trial [@B6], [@B7], which is a multicenter study on gastric cancer developed to collect information on the surgical, clinical, and oncological features of patients undergoing gastrectomy with a robotic, laparoscopic, or open approach. To the best of our knowledge, this study is the first large-scale case-control study to compare the surgical outcomes of laparoscopic gastrectomy (LG) for gastric cancer between the east and west.

Patients and Methods
====================

Patients
--------

This study is a multi-institutional retrospective study that compares the short-term outcomes of LG for gastric carcinoma between eastern and western countries. Data collection started after reporting the specific study protocol. This study was registered at clinical trials.gov with a registration number of NCT02325453. This study was approved by the ethics Committee of CEAS Umbria. Tailored Web-based software was developed to standardize information, facilitate the process of data collection in a unified multi-institutional database, and guarantee the proper storage of patient\'s data. The purpose was to create an international registry with a high methodological quality. In the present study, the data regarding procedures performed up to the data collection (from January 2009 to August 2016) that entered into the IMIGASTRIC registry were analyzed. All involved centers were referral institutions with well-established gastric cancer programs and experience in minimally invasive surgery. All diagnostic and surgical interventions at these centers were performed according to international guidelines and the information stored in institutional prospective data collection systems. The inclusion criteria were as follows: gastric cancer reported in the biopsy report; upper endoscopy and CT scan for staging; either early or advanced gastric cancer; and curative surgery. The exclusion criteria were as follows: evidence of metastatic disease, a history of another surgery for gastric cancer, emergency surgery with bleeding or perforation, another malignancy, and surgery with palliative intent. Finally, 1858 eastern patients (from three centers) and 253 western patients (from ten centers) were included in the study. The surgical procedures were described in detail as follows: 1) total or subtotal gastrectomy was performed, according to the tumor location, size, and depth of invasion, and 2) D1+/D2 lymphadenectomy was undertaken according to the rules of the Japanese Research Society for Gastric Cancer [@B8], [@B9]. Tumor staging was performed according to the 8th edition of the International Union against Cancer (UICC) TNM classification [@B10].

Patients were observed for 30 days following surgery, and short-term surgical outcomes including the operation time, estimated blood loss, postoperative complications, length of postoperative hospital stay, number of dissected lymph nodes (LNs) and clinicopathological characteristics were recorded in a web-based system (<https://imigastric.logix-software.it/>). Then, the data were extracted using pre-established IT tools. Postoperative complications were classified according to the revised version of the Clavien-Dindo classification system suggested by Dindo et al. [@B11], [@B12]. Types of postoperative complications were classified in accordance with the Japan Clinical Oncology Group Postoperative Complication Criteria according to the Clavien-Dindo classification ver. 2.0 [@B13]. The operation time was measured from the first skin incision to the closure of all skin incisions with skin staples. The mortality rate was defined as death within 30 days or in-hospital mortality when admitted beyond 30 days.

Statistical analysis
--------------------

All statistical analyses were performed using SPSS v18.0 for Windows (SPSS Inc., Chicago, IL). The data are presented as the mean ± standard deviation for continuous variables and as a number for categorical variables. For non-parametric data, variables were reported as the median (interquartile range). The differences in the patient demographics, surgical variables and pathological variables between the groups were calculated by using Fisher\'s exact test, the *t-*test, or the chi square test as appropriate. To evaluate the predictive factors for postoperative morbidity, a multivariate analysis was performed with binary logistic multiple regression analysis using dummy variables. P values less than 0.05 were considered statistically significant.

Results
=======

Patient clinicopathological characteristics
-------------------------------------------

The clinicopathological characteristics of the 2111 patients (1858 eastern vs. 253 western) are listed in Table [1](#T1){ref-type="table"}. The western cohort comprised more elderly patients, more female patients, and patients with a higher body mass index (BMI) and a higher ASA score than the eastern cohort (all P\<0.05). The proportion of patients with previous surgery and neoadjuvant chemotherapy was significantly higher in the western cohort than in the eastern cohort (both P\<0.05). However, no significant differences in comorbidities were evident between the two cohorts (P\>0.05).

There were more eastern patients than western patients had upper 1/3 tumors (31.9% in the east vs. 15.4% in the west; P\<0.05). The eastern patients had a higher percentage of differentiated tumors with higher T stage and N stage compared to Western patients (all P\<0.05). The median tumor size was similar between the cohorts (P\>0.05).

Surgical characteristics
------------------------

The type of resection, type of reconstruction and anastomosis approach were significantly different between the cohorts (all P\<0.05). The number of conversions to open surgeries, number of intraoperative blood transfusions, operation time, and volume of estimated blood loss were significantly lower in the eastern cohort than in the western cohort (all P\<0.05). The number of patients who underwent D2 lymphadenectomy and R0 resection was significantly higher in the eastern cohort than in the western cohort (both P\<0.05). The number of received lymph nodes was higher in the east than in the west (33.5±13.1 vs. 21.2±12.6, P\<0.05) (Table [2](#T2){ref-type="table"}).

Perioperative outcomes
----------------------

The proportion of postoperative transfusions was significantly lower in the east than in the west (1.7% vs. 9.9%, P\<0.05). However, the time to NG tube removal, time to first flatus, time to start of a liquid diet, time to start of a soft diet, and the post-operative hospital stay were significantly shorter in the west than in the east (all P\<0.001, Table [2](#T2){ref-type="table"}).

One or more complications occurred in 277 patients (14.9%) in the east and 40 patients (15.8%) in the west, and no statistical significance was evident (P\>0.05). Anastomotic stenosis (0.8% vs. 0.1%, p=0.040) and urinary system complications (2.0% vs. 0.4%, p\<0.001) were more frequent in the west than in the east. However, no significant differences were evident for the other complications between the two cohorts (P\>0.05).

According to the Clavien-Dindo classification, more postoperative major complications (grade III-IV) occurred in the west than in the east (5.5% vs. 2.8%, P\<0.05), but for grade I-II or grade V complications, no significant differences were evident between the two cohorts (both P\>0.05). Among the grade I-II complications, intra-abdominal bleeding (P=0.031), pleural effusion (P=0.002), and urinary system complications (P=0.003) occurred more frequently in the west than in the east, but the most frequent in the east were associated with pneumonia (P=0.010). Among the grade III-IV complications, more western patients than eastern patients suffered from anastomotic leakage (2.4% vs. 0.5%, P=0.002) and intestinal obstruction (0.8% vs. 0.1%, P=0.040) after LG, but no significant differences were evident for the other complications between the two cohorts (P\>0.05) (Table [3](#T3){ref-type="table"}).

Predictable risk factors for postoperative complications
--------------------------------------------------------

Univariate analysis and multivariate analysis were used to evaluate the factors that influenced postoperative complications. On univariate analysis, an age \>75 years (P\<0.001), a higher ASA score (P=0.002), more comorbidities (P=0.032), and an estimated blood loss ≥75 ml (P=0.004) were significantly related to the occurrence of a postoperative complications in the east. However, in the west, comorbidities, previous surgery, neoadjuvant therapy, the anastomosis approach, combined resection, operation time, estimated blood loss, pT stage, and pN stage were significantly related to the occurrence of a postoperative complication (all P\<0.05) (Table [4](#T4){ref-type="table"}).

Multivariate analysis found that an age \>75 years (P\<0.001), a higher ASA score (P=0.017), and an estimated blood loss ≥75 ml (P=0.004) were independent risk factors for postoperative complications in the east. However, for the western patients, the independent risk factors were neoadjuvant therapy (P=0.012), the retrieval of more LNs (P=0.042), and pT3-4 stage (P\<0.05) (Table [5](#T5){ref-type="table"}).

Discussion
==========

Currently, LG is becoming more widely used worldwide and some Eastern centers have become one of the standard surgical approaches for early gastric cancer [@B9]. LG for advanced gastric cancer has been developed successfully in many centers, and the number ongoing multicenter RCTs that focus on the safety and efficacy of LG in the east is increasing [@B14]-[@B16]. For the west, in 1992, Ohgami et al. reported the first laparoscopic wedge resection (LWR) for the treatment of early gastric cancer (EGC) [@B17].

Recently, LG has become an important surgical procedure for radical gastrectomy in many western centers. However, no reports on the efficacy of LAG between the east and west centers are available. This study is the first large case-control study using multicenter clinical research data (IMIGASTRIC trial), and can be used as a preliminary basis for future prospective studies. In this study, the 1858 patients in the east and 253 patients in the west had significant differences in demographic, clinical, and pathologic characteristics. Patient characteristics such as age, and BMI and the ASA score were higher in the west. This result may be due to epidemiological differences between the east and west [@B18]. However, differences in the selection of laparoscopic surgery cases between the east and west may have influenced the results. Hamashima C KY et al. found that the age of population-based screening is early in eastern countries, resulting in an age of onset that is lower in the east than in the west [@B19]. The higher BMI in the western patient group may correspond to an overall higher BMI in the western population. Regarding the pathological features, more undifferentiated earlier-stage tumors were evident in the west than in the east for laparoscopic surgery, which was consistent with the study by Strong VE et al. [@B20]. In addition, we found that the majority of patients in both cohorts had tumors in the distal stomach, but the proportion of upper 1/3 tumors was significantly higher in the east than in the west (31.9% vs. 15.4%, P\<0.05), which was contrary to previous studies [@B18]. Laparoscopic total gastrectomy for proximal gastric cancer is a difficult procedure, and fewer western centers may choose this approach for laparoscopic surgery. However, in the east, the number of gastric cancer cases was higher, the patients were younger and had less BMI, and these factors increased the number of options for laparoscopic surgery. Recently, several studies have shown that the incidence of proximal gastric cancer in the east has increased annually [@B21]-[@B23], possibly explaining higher proportion Eastern patients undergoing proximal and total gastrectomy in the current study.

The number of conversion to open surgeries, number of blood transfusions, and volume of estimated blood loss were higher in the west than in the east, and the operation time was longer in the west than in the east; however, the number of LN dissections was lower in the west than in the east. These observations may be attributed to differences in the patient characteristics between the east and west. More options for the treatment of early gastric cancer exist in the west than in the east, so the extent of LN dissection is smaller. Due to several factors in the west, such as the lower overall incidence of gastric cancer and higher BMI, which can increase the difficulty of laparoscopic operation, the number of conversions to open surgery, the operation time, and the volume of estimated blood loss were higher in the west than in the east. In the east, the data have suggested a learning curve number of 20-40 procedures [@B24]. In another report from the west, Kunisaki C et al. showed that the learning curve for surgeons comprised approximately 60 cases, after which the operation time significantly improved with equivalent LN retrievals and surgical outcomes [@B25]. The incidence of gastric cancer is lower in the west than in the east. However, the learning curve for performing minimally invasive gastrectomy requires more cases. When we compared postoperative recovery between the west and east, we found that the time to NG tube removal, time to first flatus, time to start of a liquid diet, time to the start of a soft diet and postoperative hospital stay were significantly shorter in the west than in the east, which may be related to the early implementation and application of enhanced recovery protocols (ERAS).

The incidence of postoperative complications is still the most frequently used surrogate marker of the \'quality\' of surgery. Previous reported morbidity rates for laparoscopic surgery vary from 6.1 to 25.4% [@B15], [@B26]-[@B28]. In this study, the postoperative morbidity was 14.9% in the east and 15.8% in the west, without significant differences. When the complications were categorized with the Clavien-Dindo classification, we found that grade III-IV complications occurred more frequently in the west than in the east (5.5% vs. 2.8%, P\<0.05), which mainly contributed to the higher incidence of anastomotic leakage and intestinal obstruction. In the west, due to early drain removal or no drain placed after surgery, when anastomotic leakage or other complications occur, more invasive procedures, such as abdominal paracentesis and drainage were performed, and lead to increases in the grade of complications. Multivariate analysis further revealed that an elderly age, a higher ASA score, and a higher estimated blood loss were the independent risk factors for postoperative complications in the east, which was consistent with several previous eastern studies [@B29], [@B30]. In the west, neoadjuvant therapy, pT3-4 and the number of LN dissections were the independent risk factors for postoperative morbidity, which suggested that advanced gastric cancer and a wider range of LN dissection would increase the incidence of postoperative complications in the western centers. Haskins and Badgwell et al. reported that postoperative morbidity and mortality were not increased by neoadjuvant therapy [@B31], [@B32]. However, the open and laparoscopic groups were not analyzed separately in these studies, which may have caused the results to be different from those of the present study. Most of the gastric cancer patients who underwent neoadjuvant therapy had more advanced stages and needed larger extents of LN dissection, increasing the difficulty of the operation and the likelihood of morbidity, especially for laparoscopic surgery with higher technical requirements.

In conclusion, distinct differences are evident between the east and west regarding the clinicopathological characteristics and short-outcomes of laparoscopic surgery for gastric cancer. Although no significant differences in overall complications were evident between the two cohorts, the major postoperative complications (grade III-IV) and risk factors for morbidity were significantly different. Therefore, for the prospective study of the efficacy of laparoscopic radical gastrectomy for gastric cancer between the east and west, we should recognize the objective factors and pay more attention to the surgical indications and case selections to obtain more objective and accurate results.
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###### 

Patient demographics and tumor finding between the eastern and western centers

  Characteristics            All patients (n=2111)   X^2^/*t*    P         
  -------------------------- ----------------------- ----------- --------- ---------
  Age                                                            154.04    \<0.001
  \<40                       65(3.5)                 7(2.8)                
  40-75                      1607(86.5)              149(58.9)             
  \>75                       186(10.0)               97(38.3)              
  Mean(±SD)                  61.0±11.2               69.4±12.8   10.92     \<0.001
  Sex                                                            66.65     \<0.001
  Male                       1407(75.7)              130(51.4)             
  Female                     451(24.3)               123(48.6)             
  Body mass index (kg/m2)    22.2±3.2                25.9±14.1   7.24      \<0.001
  ASA score                                                      1027.96   0.000
  1                          1139(61.3)              12(4.7)               
  2                          646(34.8)               57(22.5)              
  3                          66(3.6)                 182(71.9)             
  4                          7(0.4)                  2(0.8)                
  Comorbidities                                                  3.48      0.062
  Yes                        1276(68.7)              159(62.8)             
  No                         582(31.3)               94(37.2)              
  Previous surgery                                               6.18      0.013
  Yes                        413(22.2)               74(29.2)              
  No                         1445(77.8)              179(70.8)             
  Neoadjuvant chemotherapy                                       66.60     \<0.001
  Yes                        42(2.3)                 31(12.3)              
  No                         1803(97.0)              222(87.7)             
  Tumor Location                                                 34.30     \<0.001
  Upper                      593(31.9)               39(15.4)              
  Middle                     453(24.4)               93(36.8)              
  Lower                      812(43.7)               121(47.8)             
  Tumor size(cm)             4.6±2.7                 4.8±5.7     0.253     0.800
  Histologic type                                                16.73     \<0.001
  Differentiated             1308(70.4)              146(57.7)             
  Undifferentiated           550(29.6)               107(42.3)             
  No. metastatic LNs                                                       
  pT stage                                                       137.91    \<0.001
  T1                         438(23.6)               126(49.8)             
  T2                         200(10.8)               35(13.8)              
  T3                         532(28.6)               69(27.3)              
  T4a                        685(36.9)               18(7.1)               
  T4b                        3(0.2)                  5(2.0)                
  pN stage                                                       73.46     \<0.001
  N0                         655(35.3)               156(61.7)             
  N1                         269(14.5)               35(13.8)              
  N2                         307(16.5)               27(10.7)              
  N3a                        380(20.5)               29(11.5)              
  N3b                        247(13.3)               6(2.4)                
  pTNM stage                                                     110.72    \<0.001
  IA                         365(19.6)               110(43.5)             
  IB                         152(8.2)                33(13.0)              
  IIA                        185(10.0)               30(11.9)              
  IIB                        206(11.1)               24(9.5)               
  IIIA                       189(10.2)               16(6.3)               
  IIIB                       299(16.1)               28(11.1)              
  IIIC                       462(24.9)               12(4.7)               

###### 

Surgical procedures between the eastern and western centers

  Characteristics                      All patients (n=2111)   X^2^/*t*       P         
  ------------------------------------ ----------------------- -------------- --------- ---------
  Type of resection                                                           73.18     \<0.001
  Distal gastrectomy                   811(43.6)               170(67.2)                
  Total gastrectomy                    1007(54.2)              69(27.3)                 
  Proximal gastrectomy                 39(2.1)                 12(2.1)                  
  Pylorus-preserving gastrectomy       1(0.1)                  2(0.8)                   
  Type of reconstruction                                                      1095.99   \<0.001
  B-I                                  682(36.7)               0(0.0)                   
  B-II                                 121(6.5)                37(14.6)                 
  Rou-en-Y GJ                          8(0.4)                  133(52.6)                
  Roux-en-Y EJ                         1007(54.2)              66(26.1)                 
  Jejunal interposition                0(0.0)                  4(1.6)                   
  Esophagogastrostomy                  39(2.1)                 11(4.3)                  
  Gastro-gastrostomy                   1(0.1)                  2(0.8)                   
  Anastomosis approach                                                        1019.24   \<0.001
  intra-corporeal                      99(5.3)                 203(80.2)                
  extra-corporeal                      1759(94.7)              50(19.8)                 
  Extent of LN dissection                                                     603.87    \<0.001
  D1                                   15(0.8)                 50(19.8)                 
  D1+                                  13(0.7)                 55(21.7)                 
  D2                                   1830(98.5)              148(58.5)                
  No. of retrieved lymph nodes         33.5±13.1               21.2±12.6      -14.06    \<0.001
  Residual tumor                                                              12.54     0.002
  R1                                   28(1.5)                 12(4.7)                  
  R0                                   1830(98.5)              241(95.3)                
  Conversion to open                                                          109.60    \<0.001
  Yes                                  1(0.1)                  16(6.3)                  
  No                                   1857(99.9)              237(93.7)                
  Operation time (min)                 179.1±53.7              217.0±84.6.2   9.71      \<0.001
  Estimated blood loss (ml)            74.8±101.0              129.1±153.4    6.99      \<0.001
  Intraoperative blood transfusion                                            22.43     \<0.001
  Yes                                  45(2.4)                 20(7.9)                  
  No                                   1813(97.6)              233(92.1)                
  Postoperative transfusions                                                  56.425    \<0.001
  Yes                                  32(1.7)                 25(9.9)                  
  No                                   1826(98.3)              228(90.1)                
  NG tube removal (days)               5.1±3.0                 2.8±2.8        -4.31     \<0.001
  Time to first flatus (days)          3.7±1.3                 2.7±1.0        -6.95     \<0.001
  Time to start of liquid diet(days)   5.1±1.8                 2.3±2.1        -13.77    \<0.001
  Time to start of soft diet (days)    7.9±2.9                 3.3±1.9        -14.61    \<0.001
  Postoperative hospital stay (days)   13.1±8.1                8.1±8.2        -9.93     \<0.001

###### 

Postoperative complications between the eastern and western centers according to Clavien-Dindo classification

  Characteristics              All patients (n=2111)   X^2^/*t*   P        
  ---------------------------- ----------------------- ---------- -------- -------
  **Total complications**      277(14.9)               40(15.8)   0.142    0.706
  **I-II complications**       223(12.0)               24(9.5)    1.264    0.243
  Abdominal infection          28(1.5)                 3(1.2)     0.159    0.690
  Anastomotic leakage          21(1.1)                 0          2.888    0.089
  Anastomotic site bleeding    5(0.3)                  3(1.2)     4.956    0.060
  Anastomotic stenosis         0                       1(0.4)     7.347    0.120
  Delayed gastric emptying     14(0.8)                 1(0.4)     0.405    0.524
  Intestinal obstruction       22(1.2)                 1(0.4)     1.286    0.257
  Intra-abdominal bleeding     2(0.1)                  2(1.3)     10.247   0.031
  Chylous leakage              13(0.7)                 0          1.781    0.182
  Pancreatic fistula           4(0.2)                  0          0.546    1.000
  Pleural effusion             0                       3(1.2)     22.063   0.002
  Pneumonia                    62(3.3)                 1(0.4)     6.655    0.010
  Wound infection              25(1.3)                 2(0.8)     0.461    0.543
  Circulatory system           4(0.2)                  0          0.546    1.000
  Hematological system         3(0.2)                  2(0.8)     3.729    0.112
  Urinary system               8(0.4)                  5(2.0)     8.693    0.003
  Other                        12(0.6)                 0          1.643    0.200
  **III-IV complications**     52(2.8)                 14(5.5)    5.499    0.019
  Abdominal infection          2(0.1)                  1(0.4)     1.298    0.255
  Anastomotic leakage          10(0.5)                 6(2.4)     9.950    0.002
  Anastomotic site bleeding    5(0.3)                  1(0.4)     0.125    0.724
  Anastomotic stenosis         1(0.1)                  1(0.4)     2.743    0.225
  Intestinal obstruction       1(0.1)                  2(0.8)     8.516    0.040
  Intra-abdominal bleeding     10(0.5)                 1(0.4)     0.088    0.767
  Pneumonia                    12(0.6)                 0          1.643    0.200
  Sepsis                       3(0.2)                  1(0.4)     0.644    0.400
  Wound infection              2(0.1)                  0          0.273    1.000
  Circulatory system           4(0.2)                  0          0.546    1.000
  Disseminated intravascular   2(0.1)                  0          0.273    1.000
  Acute renal failure          0                       1(0.4)     7.347    0.120
  **V complications**          2(0.1)                  2 (0.8)    5.490    0.073

###### 

Univariate analysis of morbidity risk factors for eastern and western laparoscopy gastrectomy

  Variable                         Eastern Centers               Western Centers                                  
  -------------------------------- ----------------- ----------- ----------------- ----- ------------ ----------- -------
  Age                                                            0.000                                            0.370
  \<40                             63(4.0)           2(0.7)                              7(3.3)       0           
  40-75                            1381(87.3)        226(81.6)                           127(59.6)    22(55.0)    
  \>75                             137(8.7)          49(17.7)                            79(37.1)     18(45.0)    
  Sex                                                            0.120                                            0.878
  Male                             1187(75.1)        220(79.4)                           109(51.2)    21(52.5)    
  Female                           394(24.9)         57(20.6)                            104(48.8)    19(47.5)    
  BMI(kg/m2)                                                     0.636                                            0.198
  \<25                             1275(80.6)        220(79.4)                           35(51.5)     16(66.7)    
  ≥25                              306(19.4)         57(20.6)                            33(48.5)     8(33.3)     
  ASA score                                                      0.002                                            0.764
  1                                987(62.4)         152(54.9)                           11(5.2)      1(2.5)      
  2                                541(34.2)         105(37.9)                           48(22.5)     9(22.5)     
  3-4                              53(3.4)           20(7.2)                             154(72.3)    30(75.0)    
  Comorbidities                                                  0.032                                            0.004
  No                               1101(69.6)        175(63.2)                           142(66.7)    17(42.5)    
  Yes                              480(30.4)         102(36.8)                           71(33.3)     23(57.5)    
  Previous surgery                                               0.488                                            0.017
  No                               1234(78.1)        211(76.2)                           157(73.7)    22(55.0)    
  Yes                              347(21.9)         66(23.8)                            56(26.3)     18(45.0)    
  Neoadjuvant therapy                                            0.446                                            0.007
  No                               1547(97.8)        269(97.1)                           192(90.1)    30(75.0)    
  Yes                              34(2.2)           8(2.9)                              21(9.9)      10(25.0)    
  Tumor location                                                 0.858                                            0.858
  Upper                            504(31.9)         89(32.1)                            504(31.9)    89(32.1)    
  Middle                           389(24.6)         64(23.1)                            389(24.6)    64(23.1)    
  Total                            688(43.5)         124(44.8)                           688(43.5)    124(44.8)   
  Tumor size(cm)                                                 0.890                                            0.205
  \<4.6 cm                         829(52.4)         144(52.0)                           54(58.1)     16(72.70)   
  ≥4.6 cm                          752(47.6)         133(48.0)                           39(41.9)     6(27.3)     
  Anastomosis approach                                           0.516                                            0.027
  Intra-corporeal                  82(5.2)           17(6.1)                             176(82.6)    27(67.5)    
  Extra-corporeal                  1499(94.8)        260(93.9)                           37(17.4)     13(32.5)    
  Type of resection                                              0.932                                            0.798
  Distal gastrectomy               687(43.5)         124(44.8)                           145(68.1)    25(62.5)    
  Total gastrectomy                859(54.3)         148(53.4)                           56(26.3)     13(32.5)    
  Proximal gastrectomy             34(2.2)           5(1.8)                              10(4.7)      2(5.0)      
  Pylorus-preserving gastrectomy   1(0.1)            0                                   2(0.19       0           
  Type of reconstruction                                         0.923                                            0.630
  B-I                              581(36.7)         101(36.5)                           0            0           
  B-II                             99(6.3)           22(7.9)                             34(16.0)     3(7.5)      
  Roux-en-Y GJ                     7(0.4)            1(0.4)                              111(52.1)    22(55.0)    
  Roux-en-Y EI                     869(54.3)         148(53.4)                           56(26.3)     14(35.0)    
  Esophagogastrostomy              34(2.2)           5(1.8)                              10(4.7)      1(2.5)      
  Gastrogastrostomy                1(0.1)            0                                   2(0.9)       0           
  Type of lymphadenectomy                                        0.659                                            0.889
  D1/ D1+                          23(1.5)           5(1.8)                              88(41.3)     17(42.5)    
  D2                               1558(98.5)        272(98.2)                           125(58.7)    23(57.5)    
  Combined resection                                             0.058                                            0.006
  No                               1419(89.8)        238(85.9)                           178(83.6)    26(65.0)    
  Yes                              162(10.2)         39(14.1)                            35(16.4)     14(35.0)    
  Operation time (min)                                           0.151                                            0.028
  \<180                            1167(73.8)        193(69.7)                           120(56.3)    15(37.5)    
  ≥180                             414(26.2)         84(30.3)                            93(43.7)     25(62.5)    
  Estimated blood loss (ml)                                      0.004                                            0.006
  \<75                             1277(80.8)        203(73.3)                           121(72.0)    18(48.6)    
  ≥75                              304(19.2)         74(2.7)                             47(28.0)     19(51.4)    
  No. of retrieved LNs                                           0.102                                            0.086
  \<34                             881(55.7)         169(61.0)                           127(59.6)    18(45.0)    
  ≥34                              700(44.3)         108(39.0)                           86(40.4)     22(55.0)    
  Histological                                                   0.775                                            0.775
  Differentiated                   1115(70.5)        193(69.7)                           1115(70.5)   193(69.7)   
  Undifferentiated                 466(29.5)         84(30.3)                            466(29.5)    84(30.3)    
  pT stage                                                       0.672                                            0.046
  T1                               373(23.6)         65(23.5)                            106(49.8)    20(50.0)    
  T2                               176(11.1)         24(8.7)                             32(15.0)     3(7.5)      
  T3                               447(28.3)         85(30.7)                            60(28.2)     9(22.5)     
  T4                               585(40.0)         103(37.2)                           15(7.0)      8(20.0)     
  pN stage                                                       0.140                                            0.030
  N0                               570(36.1)         85(30.7)                            132(62.0)    24(60.0)    
  N1                               224(14.2)         45(16.2)                            33(15.5)     2(5.0)      
  N2                               266(16.8)         41(14.8)                            24(11.3)     3(7.5)      
  N3a                              310(19.6)         70(25.3)                            19(8.9)      10(25.0)    
  N3b                              211(13.3)         36(13.0)                            5(2.3)       1(2.5)      
  pTNM stage                                                     0.683                                            0.188
  IA                               311(19.7)         54(19.5)                      I     122(57.3)    21(52.5)    
  IB                               135(8.5)          17(6.1)                       II    48(22.5)     6(15.0)     
  IIA                              162(10.2)         23(8.3)                       III   43(20.2)     13(32.5)    
  IIB                              170(10.8)         36(13.0)                                                     
  IIIA                             160(10.1)         29(10.5)                                                     
  IIIB                             254(16.1)         45(16.2)                                                     
  IIIC                             389(24.6)         73(26.4)                                                     

###### 

Multivariate analysis of the morbidity for eastern and western laparoscopy gastrectomy

  Variable               B        S.E     Wals     P       OR       95%CI
  ---------------------- -------- ------- -------- ------- -------- --------------
  **Eastern centers**                                               
  Age                    0.773    0.173   20.064   0.000   2.166    1.545-3.038
  ASA score              0.369    0.155   5.660    0.017   1.446    1.067-1.960
  Comorbidities          0.198    0.203   0.953    0.329   1.219    0.819-1.814
  Combined resection     -0.343   0.195   3.092    0.079   0.710    0.484-1.040
  Estimated blood loss   0.439    0.152   8.353    0.004   1.551    1.152-2.089
  Constant               -3.842   0.532   52.222   0.000   0.021    
  **Western centers**                                               
  Comorbidities          -0.244   0.592   0.169    0.681   0.784    0.245-2.502
  Previous surgery       -0.617   0.686   0.810    0.368   0.539    0.141-2.069
  Neoadjuvant therapy    -1.471   0.584   6.345    0.012   0.230    0.073-0.722
  Anastomosis approach   -0.583   0.540   1.167    0.280   0.558    0.194-1.608
  Combined resection     -0.179   0.583   0.094    0.759   0.836    0.267-2.623
  Operation time         -0.142   0.685   0.043    0.836   0.867    0.227-3.322
  Estimated blood loss   -0.677   0.650   1.086    0.297   0.508    0.142-1.816
  No. of retrieved LNs   -0.933   0.459   4.136    0.042   0.394    0.160-0.967
  pT stage                                7.792    0.051            
  pT1 vs pT2             -0.866   0.781   1.227    0.268   0.421    0.091-1.946
  pT1 vs pT3             -1.926   0.981   3.855    0.050   0.146    0.021-0.997
  pT1 vs pT4             -1.931   0.796   5.889    0.015   0.145    0.030-0.690
  pN stage                                5.827    0.212            
  pN0 vs pN1             0.102    1.736   0.003    0.953   1.107    0.037-33.265
  pN0 vs pN2             -1.544   1.861   0.688    0.407   0.214    0.006-8.204
  pN0 vs pN3a            -0.987   1.817   0.295    0.587   0.373    0.011-13.116
  pN0 vs pN3b            0.470    1.717   0.295    0.784   1.600    0.055-46.320
  Constant               3.019    1.791   2.843    0.092   20.481   
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